The new firm, which will focus on aggregating biopharmaceutical technologies and performing proof-of-concept work in developmental trials, recently acquired all intellectual property (IP) and assets from US-based biotechnology group Telemolecular.
Under that deal, RCP will retain Telemolecular’s research laboratory in Sacramento as its primary US R&D site. RCP also plans to increase the number of scientific staff at the Californian facility, which will also be developed as a US commercialisation base for its products.
Company CEO Robert Sexauer said that: “Our vision for the Company is focused on the convergence between nanotechnologies and cellular targeting in the area of regenerative medicine.”
He added: “We are actively seeking to acquire IP rights to prime technology candidates in the field of regenerative medicine,” adding that the company plans “to forge alliances with leading European research institutions to commercialise cell based technologies.”
In relation to choosing London in the UK as its base, Sexauer said that the location provides “access to high quality research facilities with good potential for collaborative partnerships.”
“We believe that we can organise and conduct Phase I clinical studies faster and [with less expense] in the EU, especially in Eastern Europe. Indeed, clinical trials can be conducted under identical guidelines established by the FDA which has shown acceptance of data gathered in EU trials,” added Sexauer.
He also suggested that RCP may set up additional European R&D facilities in the future and added that the “aggressive efforts” and tax incentives being offered by European governments to assist the development of the emerging biotechnology sector would be a significant factor in any such decision.